ClinicalTrials.gg
CompletedNCT04489771Updated Sep 24, 2026Results posted

A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

A Phase 2 interventional study of Belzutifan in Carcinoma, Renal Cell, sponsored by Merck Sharp & Dohme LLC. Completed at 48 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing belzutifan in Carcinoma, Renal Cell — 5 open to participants now, 13 under way, 5 of them phase 3. belzutifan · Carcinoma, Renal Cell.

Enrollment
8th of 18
154 · median 135
Started
2020
with 4 others
Phase 2
7 of 18
5 open now
Registered
4th of 18
by date
Lead sponsor
10 of 18
Merck Sharp & Dohme LLC

Among the 18 studies testing belzutifan in Carcinoma, Renal Cell, this one is the 8th largest by enrollment, is one of 5 that started in 2020, is one of 7 in phase 2, and was the 4th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

5 of the 18 studies testing belzutifan in Carcinoma, Renal Cell are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About belzutifan

belzutifan: first FDA approval 2021 (WELIREG), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing belzutifan in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.

The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate (ORR).

03

Conditions studied

  • Carcinoma, Renal Cell

Keywords

  • Hypoxia inducible factor (HIF)
  • Hypoxia inducible factor 1B (HIF-1B)
  • Hypoxia inducible factor 2 alpha (HIF-2 alpha)
  • Hypoxia inducible factor 2α (HIF-2α)
  • Renal Cell Carcinoma (RCC)
  • Kidney cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a confirmed diagnosis of locally advanced/ RCC with clear cell component
  • Has per 1.1 as assessed by BICR
  • Can submit an sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
  • Has experienced disease progression on or after systemic treatment with an anti-programmed cell death 1 ()/Ligand 1 (L1) therapy for locally advanced or metastatic RCC. The anti-PD-1/L1 therapy may be monotherapy or in combination with other agent(s) such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) or vascular endothelial growth factor (VEGF) targeted- tyrosine kinase inhibitor (TKI). The immediately preceding has to have been an anti-PD-1/L1 therapy
  • Has received no more than 3 prior systemic regimens for locally advanced or metastatic RCC
  • Has received only 1 prior anti-PD-1/L1 therapy for locally advanced or metastatic RCC
  • Has recovered from all AEs due to previous therapies to ≤Grade 1 or baseline, with the exception of ≤Grade 2 neuropathy or endocrine-related AEs ≤Grade 2 requiring treatment or hormone replacement
  • Has a performance status (KPS) score of at least 70% assessed within 10 days prior to the first dose of study intervention
  • A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use during the intervention period and for at least 7 days after the last dose of study intervention
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a (woman of ) WOCBP or a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention
  • A WOCBP must have a negative highly sensitive pregnancy test (urine or serum) within 24 hours before the first dose of study intervention

Exclusion criteria

Exclusion Criteria:

  • Has hypoxia (a pulse oximeter reading \<92% at rest), requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
  • Has a known additional that is progressing or has required active treatment within the past 3 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ [e.g., breast carcinoma, cervical cancer in situ] that have undergone potentially curative therapy
  • Has known central nervous system (CNS) and/or carcinomatous meningitis
  • Has cardiac disease, including unstable angina, acute myocardial infarction ≤6 months from Day 1 of study drug administration or Class III or IV congestive heart failure
  • Has moderate to severe hepatic impairment ( B or C)
  • Has received colony-stimulating factors (eg, granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin [EPO]) ≤28 days prior to the first dose of study intervention
  • Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study
  • Is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (eg, gastrectomy, partial bowel obstruction, malabsorption)
  • Has known or allergy to the active pharmaceutical ingredient or any component of the study intervention (belzutifan) formulations
  • Has received prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α inhibitor
  • Has received any type of small molecule kinase inhibitor (including kinase inhibitor) ≤2 weeks before randomization
  • Has received any type of systemic anticancer antibody (including investigational antibody) ≤4 weeks before randomization
  • Has received prior radiotherapy ≤2 weeks prior to first dose of study intervention. Participants must have recovered from all radiation-related toxicities and not require
  • Has had major surgery ≤3 weeks prior to first dose of study intervention
  • Is currently receiving either strong (phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate (eg, bosentan, efavirenz, modafinil) inducers of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study
  • Is currently participating in a study of an investigational agent or is currently using an investigational device
  • Has an active infection requiring systemic therapy
  • Has active tuberculosis (TB)
  • Has a diagnosis of immunodeficiency
  • Has a known history of (HIV) infection
  • Has a known history of (HBV) or known active (HCV) infection
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not the best interest of the participant to participate, in the opinion of the treating investigator
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Belzutifan 200 mg

    Participants receive 200 mg of belzutifan by oral administration, once a day (QD), until disease progression or discontinuation.

    Drug: Belzutifan

  • Experimental
    Belzutifan 120 mg

    Participants receive 120 mg of belzutifan by oral administration, QD, until disease progression or discontinuation.

    Drug: Belzutifan

Interventions

  • Oral administration

    Also known as: MK-6482, PT2977, WELIREG™

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

    ORR was defined as the percentage of participants who had a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experienced a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented.

    Time frame: Up to approximately 27 months

Secondary outcomes

  1. Progression-Free Survival (PFS) According to RECIST 1.1 as Assessed by BICR

    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by blinded independent central review was presented.

    Time frame: Up to approximately 27 months

  2. Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR

    For participants who demonstrated a confirmed complete response (CR: Disappearance of all target lesions) or confirmed partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. The DOR as assessed by blinded independent central review was presented.

    Time frame: Up to approximately 27 months

  3. Clinical Benefit Rate (CBR) Per RECIST 1.1 as Assessed by BICR

    CBR is defined as the percentage of participants who have a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) or stable disease (SD: Neither sufficient decrease to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.) ≥6 months per RECIST 1.1. The percentage of participants with CBR will be presented.

    Time frame: Up to approximately 27 months

  4. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 27 months

  5. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced one or more AEs was presented.

    Time frame: Up to approximately 27 months

  6. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE was presented.

    Time frame: Up to approximately 26 months

  7. Maximum Plasma Concentration (Cmax) of Belzutifan

    Blood samples were obtained at designated time points for the determination of the Cmax of belzutifan.

    Time frame: Weeks 1 and 3 on Day 1: predose and 1, 2, and 4 hours. Week 5 on Day 1: predose only

  8. Trough Plasma Concentration (Ctrough) of Belzutifan

    Blood samples were obtained at designated time points for the determination of the Ctrough of belzutifan.

    Time frame: Weeks 1 and 3 on Day 1: predose and 1, 2, and 4 hours. Week 5 on Day 1: predose only

07

Results

Posted Feb 28, 2024

Participant flow

Participant flow — Overall Study
MilestoneBelzutifan 200 mgBelzutifan 120 mg
Started7876
Completed00
Not completed7876
Withdrew: Death2725
Withdrew: Withdrawal by subject10
Withdrew: Participants ongoing in study5051

Outcome measures

PrimaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

ORR was defined as the percentage of participants who had a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experienced a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented.

Time frame:
Up to approximately 27 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Percentage of ParticipantsBelzutifan 200 mgBelzutifan 120 mg
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)23.1 (14.3 to 34.0)23.7 (14.7 to 34.8)
Statistical analysis
  • Belzutifan 200 mg vs Belzutifan 120 mg · Miettinen & Nurminen · p = 0.5312 (One-sided p-value for testing. H0: difference in % = 0 versus H1: difference in % \> 0.) · Difference in percentage: -0.5 · 95% CI -14.0 to 12.9Belzutifan 200 mg minus Belzutifan 120 mg
SecondaryProgression-Free Survival (PFS) According to RECIST 1.1 as Assessed by BICR

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by blinded independent central review was presented.

Time frame:
Up to approximately 27 months
Reported as:
Median · Months
Progression-Free Survival (PFS) According to RECIST 1.1 as Assessed by BICR
MonthsBelzutifan 200 mgBelzutifan 120 mg
Progression-Free Survival (PFS) According to RECIST 1.1 as Assessed by BICR9.1 (5.5 to 12.0)7.3 (5.6 to 9.5)
Statistical analysis
  • Belzutifan 200 mg vs Belzutifan 120 mg · Log Rank · p = 0.3861 (No formal hypothesis testing performed; nominal p-value provided for treatment comparison.) · Hazard ratio (hr): 0.94 · 95% CI 0.63 to 1.40Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by IMDC risk group (favorable vs. intermediate or poor).
SecondaryDuration of Response (DOR) Per RECIST 1.1 as Assessed by BICR

For participants who demonstrated a confirmed complete response (CR: Disappearance of all target lesions) or confirmed partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. The DOR as assessed by blinded independent central review was presented.

Time frame:
Up to approximately 27 months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR
MonthsBelzutifan 200 mgBelzutifan 120 mg
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR16.1 (6.5 to NA)NA (3.8 to NA)
SecondaryClinical Benefit Rate (CBR) Per RECIST 1.1 as Assessed by BICR

CBR is defined as the percentage of participants who have a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) or stable disease (SD: Neither sufficient decrease to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.) ≥6 months per RECIST 1.1. The percentage of participants with CBR will be presented.

Time frame:
Up to approximately 27 months
Reported as:
Number · Percentage of Participants
Clinical Benefit Rate (CBR) Per RECIST 1.1 as Assessed by BICR
Percentage of ParticipantsBelzutifan 200 mgBelzutifan 120 mg
Clinical Benefit Rate (CBR) Per RECIST 1.1 as Assessed by BICR41.0 (30.0 to 52.7)47.4 (35.8 to 59.2)
Statistical analysis
  • Belzutifan 200 mg vs Belzutifan 120 mg · Miettinen & Nurminen method · p = 0.7832 · Miettinen & nurminen method: -6.3 · 95% CI -21.7 to 9.4
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause.

Time frame:
Up to approximately 27 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsBelzutifan 200 mgBelzutifan 120 mg
Overall Survival (OS)NA (20.6 to NA)NA (22.0 to NA)
Statistical analysis
  • Belzutifan 200 mg vs Belzutifan 120 mg · Log Rank · p = 0.6448 (No formal hypothesis testing performed; nominal p-value provided for treatment comparison.) · Hazard ratio (hr): 1.11 · 95% CI 0.65 to 1.90Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by IMDC risk group (favorable vs. intermediate or poor).
SecondaryNumber of Participants Who Experience One or More Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced one or more AEs was presented.

Time frame:
Up to approximately 27 months
Reported as:
Number · Number of Participants
Number of Participants Who Experience One or More Adverse Events (AEs)
Number of ParticipantsBelzutifan 200 mgBelzutifan 120 mg
Number of Participants Who Experience One or More Adverse Events (AEs)7775
SecondaryNumber of Participants Who Discontinue Study Treatment Due to an AE

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE was presented.

Time frame:
Up to approximately 26 months
Reported as:
Number · Number of Participants
Number of Participants Who Discontinue Study Treatment Due to an AE
Number of ParticipantsBelzutifan 200 mgBelzutifan 120 mg
Number of Participants Who Discontinue Study Treatment Due to an AE114
SecondaryMaximum Plasma Concentration (Cmax) of Belzutifan

Blood samples were obtained at designated time points for the determination of the Cmax of belzutifan.

Time frame:
Weeks 1 and 3 on Day 1: predose and 1, 2, and 4 hours. Week 5 on Day 1: predose only
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Belzutifan
ng/mLBelzutifan 200 mgBelzutifan 120 mg
Maximum Plasma Concentration (Cmax) of Belzutifan2512 ± 861518 ± 97
SecondaryTrough Plasma Concentration (Ctrough) of Belzutifan

Blood samples were obtained at designated time points for the determination of the Ctrough of belzutifan.

Time frame:
Weeks 1 and 3 on Day 1: predose and 1, 2, and 4 hours. Week 5 on Day 1: predose only
Reported as:
Geometric mean · ng/mL
Trough Plasma Concentration (Ctrough) of Belzutifan
ng/mLBelzutifan 200 mgBelzutifan 120 mg
Trough Plasma Concentration (Ctrough) of Belzutifan513 ± 158296 ± 159

Adverse events

Collected over Up to approximately 27 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belzutifan 200 mg28/78 (35.9%)33/78 (42.3%)75/78 (96.2%)
Belzutifan 120 mg25/76 (32.9%)33/76 (43.4%)74/76 (97.4%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventBelzutifan 200 mgBelzutifan 120 mg
HypoxiaRespiratory, thoracic and mediastinal disorders9/784/76
AnaemiaBlood and lymphatic system disorders4/784/76
PneumoniaInfections and infestations2/783/76
Cardiac failureCardiac disorders3/780/76
Chest painGeneral disorders1/782/76
HypercalcaemiaMetabolism and nutrition disorders0/782/76
HyponatraemiaMetabolism and nutrition disorders1/782/76
SyncopeNervous system disorders0/782/76
HaematuriaRenal and urinary disorders0/782/76
Atrial fibrillationCardiac disorders2/780/76
Most frequent other events
Showing 10 of 57
Most frequent other events
EventBelzutifan 200 mgBelzutifan 120 mg
AnaemiaBlood and lymphatic system disorders64/7858/76
FatigueGeneral disorders42/7840/76
NauseaGastrointestinal disorders18/7827/76
HeadacheNervous system disorders17/7822/76
Oedema peripheralGeneral disorders18/7818/76
ArthralgiaMusculoskeletal and connective tissue disorders13/7818/76
DyspnoeaRespiratory, thoracic and mediastinal disorders18/7818/76
HypoxiaRespiratory, thoracic and mediastinal disorders13/7817/76
ConstipationGastrointestinal disorders8/7815/76
DizzinessNervous system disorders11/7815/76

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Belzutifan 200 mgBelzutifan 120 mgTotal
Mean64.5 ± 9.861.6 ± 9.863.1 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Belzutifan 200 mgBelzutifan 120 mgTotal
Female191231
Male5964123
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Belzutifan 200 mgBelzutifan 120 mgTotal
Hispanic or Latino527
Not Hispanic or Latino6972141
Unknown or Not Reported426
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Belzutifan 200 mgBelzutifan 120 mgTotal
American Indian or Alaska Native000
Asian235
Native Hawaiian or Other Pacific Islander011
Black or African American336
White7169140
More than one race000
Unknown or Not Reported202
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Risk Factor
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Risk Factor(Participants)Belzutifan 200 mgBelzutifan 120 mgTotal
Favorable131427
Intermediate or Poor6562127
08

Study locations

48 sites
  • Georgetown University Medical Center ( Site 0002)
    Washington D.C., District of Columbia 20007, United States
  • Univ of Miami- Sylvester Comprehensive Cancer Center ( Site 0023)
    Miami, Florida 33136, United States
  • Norton Cancer Institute - St. Matthews ( Site 0025)
    Louisville, Kentucky 40207, United States
  • Weinberg Cancer Institute at Franklin Square ( Site 0007)
    Baltimore, Maryland 21237, United States
  • Cancer Partners of Nebraska ( Site 0003)
    Lincoln, Nebraska 68510, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0012)
    Omaha, Nebraska 68130, United States
  • New York Oncology Hematology P.C ( Site 0028)
    Albany, New York 12206, United States
  • Roswell Park Cancer Institute ( Site 0038)
    Buffalo, New York 14263, United States
  • Fox Chase Cancer Center ( Site 0026)
    Philadelphia, Pennsylvania 19111, United States
  • Sanford Cancer Center Oncology Clinic ( Site 0031)
    Sioux Falls, South Dakota 57104, United States
  • UT West Cancer Center ( Site 0032)
    Germantown, Tennessee 38138, United States
  • Urology Associates ( Site 0015)
    Nashville, Tennessee 37209, United States
  • University of Texas Southwestern Medical Center at Dallas ( Site 0004)
    Dallas, Texas 75390, United States
  • Baylor Scott & White Medical Center - Temple ( Site 0013)
    Temple, Texas 76508, United States
  • Huntsman Cancer Institute ( Site 0037)
    Salt Lake City, Utah 84112, United States
  • Inova Schar Cancer Institute ( Site 0001)
    Fairfax, Virginia 22031, United States
  • Blue Ridge Cancer Care - Roanoke ( Site 0017)
    Roanoke, Virginia 24014, United States
  • Kadlec Clinic Hematology and Oncology ( Site 0008)
    Kennewick, Washington 99336, United States
  • Macquarie University ( Site 1007)
    Macquarie University, New South Wales 2109, Australia
  • Eastern Health - Box Hill Hospital ( Site 1003)
    Box Hill, Victoria 3128, Australia
  • Peninsula Health Frankston Hospital ( Site 1001)
    Frankston, Victoria 3199, Australia
  • GZA Sint Augustinus ( Site 2003)
    Wilrijk, Antwerpen 2610, Belgium
  • Grand Hopital de Charleroi ( Site 2005)
    Charleroi, Hainaut 6000, Belgium
  • CHU de Liege ( Site 2002)
    Liège, Liege 4000, Belgium
  • UZ Gent ( Site 2004)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven ( Site 2001)
    Leuven, Vlaams-Brabant 3000, Belgium
  • General Hospital of Athens "Alexandra" ( Site 1102)
    Athens, Attica 115 28, Greece
  • Athens University Hospital ATTIKON ( Site 1100)
    Chaïdári, Attica 12 462, Greece
  • University General Hospital of Larissa ( Site 1101)
    Larissa, Thessaly 411 10, Greece
  • Cork University Hospital ( Site 9053)
    Cork, T12 DC4A, Ireland
  • Tallaght University Hospital ( Site 9051)
    Dublin, D24 NR0A, Ireland
  • Soroka Medical Center ( Site 4004)
    Beersheba, 8410101, Israel
  • Rambam Medical Center ( Site 4001)
    Haifa, 3109601, Israel
  • Rabin Medical Center ( Site 4002)
    Petah Tikva, 4941492, Israel
  • Sourasky Medical Center ( Site 4003)
    Tel Aviv, 6423906, Israel
  • Maastricht Universitair Medisch Centrum - MUMC ( Site 5001)
    Maastricht, Limburg 6202AZ, Netherlands
  • Antoni van Leeuwenhoek Ziekenhuis ( Site 5003)
    Amsterdam, North Holland 1066 CX, Netherlands
  • Isala klinieken ( Site 5002)
    Zwolle, Overijssel 8025 AB, Netherlands
  • Erasmus MC ( Site 5000)
    Rotterdam, South Holland 3015 GD, Netherlands
  • Universitair Medisch Centrum Utrecht ( Site 5004)
    Utrecht, 3584 CX, Netherlands
  • Federal state budgetary institution Russian Research Centre of radiology and nuclear medicine ( Site
    Moscow, Moscow 117997, Russia
  • City Clinical Oncology Hospital No. 1 ( Site 6004)
    Moscow, Moscow 129090, Russia
  • Clinical Research Center of specialized types medical care-Oncology ( Site 6002)
    Saint Petersburg, Sankt-Peterburg 197758, Russia
  • Russian Scientific Center of Radiology and Surgical Technologies ( Site 6001)
    Saint Petersburg, Sankt-Peterburg 197758, Russia
  • Royal Free London NHS Foundation Trust ( Site 9003)
    London, England NW3 2QG, United Kingdom
  • Imperial College Healthcare NHS Trust ( Site 9004)
    London, London, City of W6 8RF, United Kingdom
  • Churchill Hospital ( Site 9000)
    Oxford, Oxfordshire OX3 7LE, United Kingdom
  • Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 9001)
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

Publications

  • Agarwal N, Brugarolas J, Ghatalia P, George S, Haanen JB, Gurney H, Ravilla R, Van der Veldt A, Beuselinck B, Pokataev I, Suelmann BBM, Tuthill MH, Vaena D, Zagouri F, Wu J, Perini RF, Liu Y, Merchan J, Atkins MB. Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. Ann Oncol. 2024 Dec;35(12):1148-1156. doi: 10.1016/j.annonc.2024.08.2338. Epub 2024 Sep 2. PubMed 39233312 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Feb 2023, 28 months.

Results were first posted in Feb 2024, 1 year after primary completion.

Of 47 industry-sponsored phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 28 months is below that.

Counting every sponsor, half of 230 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2020
First posted
Jul 28, 2020
StartActual
Sep 13, 2020
Primary completionActual
Feb 10, 2023
CompletionActual
Aug 25, 2026
Results first posted
Feb 28, 2024
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04489771
Responsible party
Sponsor
First posted
Jul 28, 2020
Start date
Sep 13, 2020
Primary completion
Feb 10, 2023
Completion
Aug 25, 2026
Results posted
Feb 28, 2024
Last update
Sep 24, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belzutifan

Start the discussion